cv risk in t2d: role of sglt2 inhibition
Published 5 years ago • 145 plays • Length 4:41Download video MP4
Download video MP3
Similar videos
-
5:05
sglt2 inhibitors: cv outcomes data in type 2 diabetes
-
0:54
combining sglt2 inhibitors and glp-1 ras may have #cardiovascular and renal benefits in #diabetes
-
58:27
the role of sglt inhibitors in managing cvd risk in type 2 diabetes - webinar recording
-
5:41
cardiovascular benefits with sglt2 inhibition: empa-reg
-
8:24
utilizing sglt2 inhibitors in practice
-
7:04
current cv evidence across sglt2 inhibitors
-
8:24
cv risk reduction in t2d: establishing treatment goals
-
22:15
sglt-2 inhibitors for type 2 diabetes - amel arnaout, md
-
5:15
prescribing antidiabetic therapy & reducing cv risk in t2d
-
5:20
sglt2 inhibition and cvd outcomes in type 2 diabetes
-
14:53
fundamentals of sglt2i's and glp-1ra's for cv risk
-
4:14
optimizing cardiovascular, renal prognosis in diabetes with glp-1, sglt2 combination
-
5:07
sglt2 inhibitors are associated with reduced cv disease in type 2 diabetes
-
2:35
akankasha goyal, md: evolving role of sglt2 inhibitors
-
2:27
cardiovascular benefit with sglt2 inhibition
-
7:14
sglt2 inhibitors and cardiovascular outcomes in type 2 diabetes: vertis cv trial
-
6:00
early vs. late initiation of glp-1ra and sglt2 for cardiometabolic risk control
-
13:49
using sglt2-inhibitors to treat cardiac patients with diabetes
-
6:58
sglt2 inhibitors in t1d: 'people are using them now'